Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. Read more in the @EHJ doi.org/10.1093/eurhea… #CENTURYTrial #MyocardialRevascularization @ESCardio European Society of Cardiology Journals

🔴An Observational Study of Cardiovascular Outcomes of Tirzepatide vs GLP-1 Receptor Agonists 🚨New Real-World Evidence: Tirzepatide vs GLP-1 RAs for CV Outcomes in T2D A large observational study compares CV risk in patients treated with tirzepatide vs GLP-1 receptor agonists.

Potential New Dyslipidemia Treatments 1️⃣ Inclisiran reduced LDL by 44.1% and apolipoproteins by 37.5% in hypercholesterolemia. 2️⃣ Lepodisiran and Olpasiran reduced apolipoproteins by 75.7% and LDL by 16.3% in hyperlipoproteinemia(a). 3️⃣ ARO-APOC3 and Plozasiran lowered VLDL

The role of finerenone in the concomitant management of CKD-type 2 diabetes and the implication for HF prevention and treatment finerenone presents new evidence-based therapy for HFpEF/HFmrEF in addition to current application in CKD associated with T2D link.springer.com/article/10.100…

#CONFIDENCE 1⃣ + 1⃣ = 2⃣ Remarkably, kidney protection with combination therapy mathematically identical to what would be expected based on each monotherapy Finerenone (0.68) * Empagliflozin (0.71) Combination (Expected if Fully Additive): 0.48 Combination (Observed): 0.48

#ERA25 Late-Breaking session day 2 Now Michael Walsh, from Hamilton, Canada. “Spironolactone in patients undergoing maintenance dialysis: the ACHIEVE trial”. Background, reasons for trial… Active drug run-in for 60 days (excluded if K was 5.8 or higher, then blind RCT with 25

🔴2025 Guidelines on Heart Failure⤵️ #openaccess 🔹globalcardiology.info/site/article/v… #Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter #cardiotwiteros #MedX #cardiovascular #MedTwitter #medical #medEd #cardiotwitter #medicineball

🔴Management of complications after valvular interventions⤵️ State of the Art #2025Review #openaccess EuroIntervention 🔹eurointervention.pcronline.com/article/manage… #Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter

Heart murmurs

2025 ESC Guidelines for the management of myocarditis and pericarditis: Developed by the task force for the management of myocarditis and pericarditis of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC)

🚨#NEW 2025 Focused Update #ESC/#EAS #guidelines on dyslipidaemia management Key changes from the 2019 edition👇 #CardioTwitter #ESC2025 #LipidUpdate #LLT

New onset HFrEF ARNI+BB+MRA+SGLT2i ➡️ 75% ⬇️ all-cause ☠️ (26% ARR, NNT=4, 24 months) 85% ⬇️ HF 🏨 (33% ARR, NNT=3) Extend median survival 7-11 years Cost $125/month (cash pay, cost plus mail order) Worth it?

New Guidelines for post resuscitation care after cardiac arrest doi.org/10.1007/s00134…

UTI is uncommon with SGLT2i - mycotic infections are common This study has important clinical implications ⚠️ After UTI, 1 in 3 patients stopped SGLT2i Discontinuation led to higher CV & renal risk, with no reduction in recurrent UTIs. 💡 Following UTI - continue SGLT2i

VESALIUS-CV results presented at #AHA25

VESALIUS a star of this lipid session at #AHA25. Substantial and deeply clinically meaningful benefit w Repatha in primary prevention. Baseline LDL-C 122. Notable ARRs, and 20% decrease in all-cause mortality! #AHA25

OPTIMA-AF results presented at #AHA25

Case in point. For the longest time, LDL target in this patient population (high risk, no prior heart attack or stroke) was < 100. This was actually done pretty well for majority of the population with statins. New class of lipid lowering agents (pcsk9 inhibitors) comes out

Bad news for enthusiasts of left atrial appendage closure from #AHA25. CLOSURE-AF is not yet published, but reports from New Orleans indicate inferiority compared with best medical care (the trial was designed for non-inferiority, making this the most unexpected and unfavorable

ADAPT AF-DES results presented at #AHA25